Francisco Antônio Helfenstein Fonseca

Research interests

Publications

• Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve

  New England Journal of Medicine · 2020 · 10.1056/nejmoa2029603

• Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis

  Journal of the American College of Cardiology · 2019 · 10.1016/j.jacc.2019.03.011

• Cardiovascular risk and obesity

  Diabetology & Metabolic Syndrome · 2019 · 10.1186/s13098-019-0468-0

• Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis

  Journal of the American College of Cardiology · 2019 · 10.1016/j.jacc.2019.03.011

• Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019

  Arquivos Brasileiros de Cardiologia · 2019 · 10.5935/abc.20190204

• Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)

  European Heart Journal · 2018 · 10.1093/eurheartj/ehy310

• Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction

  JAMA Cardiology · 2018 · 10.1001/jamacardio.2018.0612

• Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction

  JAMA Cardiology · 2018 · 10.1001/jamacardio.2018.0612

• Monocyte subtypes and the CCR2 chemokine receptor in cardiovascular disease

  Clinical Science · 2017 · 10.1042/cs20170009

• Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1707914

• Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)32814-3

• Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)32247-x

• Monocyte subtypes and the CCR2 chemokine receptor in cardiovascular disease

  Clinical Science · 2017 · 10.1042/cs20170009

• High-Sensitivity C-Reactive Protein and Cardiovascular Disease Across Countries and Ethnicities

  Clinics · 2016 · 10.6061/clinics/2016(04)11

• High-Sensitivity C-Reactive Protein and Cardiovascular Disease Across Countries and Ethnicities

  Clinics · 2016 · 10.6061/clinics/2016(04)11

• Increased arterial stiffness in resistant hypertension is associated with inflammatory biomarkers

  Blood Pressure · 2014 · 10.3109/08037051.2014.940710

• Increased arterial stiffness in resistant hypertension is associated with inflammatory biomarkers

  Blood Pressure · 2014 · 10.3109/08037051.2014.940710

• Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein

  Obstetrical & Gynecological Survey · 2009 · https://doi.org/10.1097/01.ogx.0000344393.60303.0a

• Number Needed to Treat With Rosuvastatin to Prevent First Cardiovascular Events and Death Among Men and Women With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein

  Circulation Cardiovascular Quality and Outcomes · 2009 · 10.1161/circoutcomes.109.848473

• Number Needed to Treat With Rosuvastatin to Prevent First Cardiovascular Events and Death Among Men and Women With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein

  Circulation Cardiovascular Quality and Outcomes · 2009 · 10.1161/circoutcomes.109.848473

• Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

  The Lancet · 2009 · https://doi.org/10.1016/s0140-6736(09)60447-5

• A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism

  New England Journal of Medicine · 2009 · 10.1056/nejmoa0900241

• Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

  New England Journal of Medicine · 2008 · https://doi.org/10.1056/nejmoa0807646

• Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein

  The American Journal of Cardiology · 2007 · 10.1016/j.amjcard.2007.09.072

• Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein

  The American Journal of Cardiology · 2007 · 10.1016/j.amjcard.2007.09.072

• IV Diretriz Brasileira sobre Dislipidemias e Prevenção da Aterosclerose: Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia

  Arquivos Brasileiros de Cardiologia · 2007 · 10.1590/s0066-782x2007000700002

• I Diretriz de Prevenção da Aterosclerose na Infância e na Adolescência

  Arquivos Brasileiros de Cardiologia · 2005 · 10.1590/s0066-782x2005002500001

• I Diretriz de Prevenção da Aterosclerose na Infância e na Adolescência

  Arquivos Brasileiros de Cardiologia · 2005 · 10.1590/s0066-782x2005002500001

Current projects

No projects listed.